Natalie E Kelso1, David S Sheps1, Robert L Cook1. 1. a Department of Epidemiology , College of Public Health and Health Professions and College of Medicine, University of Florida , Gainesville , FL , USA.
Abstract
BACKGROUND: People living with HIV-infection (PLWH) have higher prevalence and earlier onset of cardiovascular disease (CVD), compared to uninfected populations. It is unclear how alcohol consumption is related to CVD among PLWH. OBJECTIVES: To summarize the current literature and strength of evidence regarding alcohol consumption as a risk factor for CVD among PLWH, to generate summary estimates for the effect of alcohol consumption on CVD outcomes, and to make recommendations for clinical practice and future research based on the findings and limitations of existing studies. METHODS: A systematic review was conducted using Pubmed/Medline to identify relevant peer-reviewed articles published between 1 January 1999 and 1 January 2014. After critical review of the literature, 13 studies were identified. Risk ratios were extracted or calculated and sample size weighted summary estimates were calculated. RESULTS: The prevalence of a CVD diagnosis or event ranged from 5.7-24.0%. The weighted pooled crude effect sizes were 1.75 (95% CI 1.06, 3.17) for general and 1.78 (95% CI 1.09, 2.93) for heavy alcohol use on CVD. The pooled adjusted effect size was 1.37 (95% CI 1.02, 1.84) for heavy alcohol use on CVD. Pooled estimates differed by CVD outcome and alcohol measure; alcohol consumption was most significant for cerebral/ischemic events. CONCLUSION: HIV clinicians should consider risk factors that are not included in the traditional risk factor framework, particularly heavy alcohol consumption. Neglect of this risk factor may lead to underestimation of risk, and thus under-treatment among PLWH.
BACKGROUND:People living with HIV-infection (PLWH) have higher prevalence and earlier onset of cardiovascular disease (CVD), compared to uninfected populations. It is unclear how alcohol consumption is related to CVD among PLWH. OBJECTIVES: To summarize the current literature and strength of evidence regarding alcohol consumption as a risk factor for CVD among PLWH, to generate summary estimates for the effect of alcohol consumption on CVD outcomes, and to make recommendations for clinical practice and future research based on the findings and limitations of existing studies. METHODS: A systematic review was conducted using Pubmed/Medline to identify relevant peer-reviewed articles published between 1 January 1999 and 1 January 2014. After critical review of the literature, 13 studies were identified. Risk ratios were extracted or calculated and sample size weighted summary estimates were calculated. RESULTS: The prevalence of a CVD diagnosis or event ranged from 5.7-24.0%. The weighted pooled crude effect sizes were 1.75 (95% CI 1.06, 3.17) for general and 1.78 (95% CI 1.09, 2.93) for heavy alcohol use on CVD. The pooled adjusted effect size was 1.37 (95% CI 1.02, 1.84) for heavy alcohol use on CVD. Pooled estimates differed by CVD outcome and alcohol measure; alcohol consumption was most significant for cerebral/ischemic events. CONCLUSION: HIV clinicians should consider risk factors that are not included in the traditional risk factor framework, particularly heavy alcohol consumption. Neglect of this risk factor may lead to underestimation of risk, and thus under-treatment among PLWH.
Authors: Matthew S Freiberg; Kathleen A McGinnis; Kevin Kraemer; Jeffrey H Samet; Joseph Conigliaro; R Curtis Ellison; Kendall Bryant; Lewis H Kuller; Amy C Justice Journal: J Acquir Immune Defic Syndr Date: 2010-02 Impact factor: 3.731
Authors: Matthew S Freiberg; Chung-Chou H Chang; Lewis H Kuller; Melissa Skanderson; Elliott Lowy; Kevin L Kraemer; Adeel A Butt; Matthew Bidwell Goetz; David Leaf; Kris Ann Oursler; David Rimland; Maria Rodriguez Barradas; Sheldon Brown; Cynthia Gibert; Kathy McGinnis; Kristina Crothers; Jason Sico; Heidi Crane; Alberta Warner; Stephen Gottlieb; John Gottdiener; Russell P Tracy; Matthew Budoff; Courtney Watson; Kaku A Armah; Donna Doebler; Kendall Bryant; Amy C Justice Journal: JAMA Intern Med Date: 2013-04-22 Impact factor: 21.873
Authors: Kenneth J Mukamal; Katherine M Conigrave; Murray A Mittleman; Carlos A Camargo; Meir J Stampfer; Walter C Willett; Eric B Rimm Journal: N Engl J Med Date: 2003-01-09 Impact factor: 91.245
Authors: Allison Ross Eckard; Paolo Raggi; Joshua H Ruff; Mary Ann O'Riordan; Julia C Rosebush; Danielle Labbato; Julie E Daniels; Monika Uribe-Leitz; Christopher T Longenecker; Grace A McComsey Journal: Virulence Date: 2017-03-21 Impact factor: 5.882
Authors: Natalie E Kelso-Chichetto; Michael Plankey; Alison G Abraham; Nicole Ennis; Xinguang Chen; Robert Bolan; Robert L Cook Journal: Am J Drug Alcohol Abuse Date: 2017-06-16 Impact factor: 3.829
Authors: N E Kelso-Chichetto; M Plankey; D S Sheps; A G Abraham; X Chen; S Shoptaw; R C Kaplan; W S Post; R L Cook Journal: Drug Alcohol Depend Date: 2017-10-28 Impact factor: 4.492
Authors: A R Webel; A Sattar; N T Funderburg; B Kinley; C T Longenecker; D Labbato; Sm Khurshid Alam; G A McComsey Journal: HIV Med Date: 2016-11-09 Impact factor: 3.180
Authors: Emily C Williams; Judith A Hahn; Richard Saitz; Kendall Bryant; Marlene C Lira; Jeffrey H Samet Journal: Alcohol Clin Exp Res Date: 2016-09-22 Impact factor: 3.455
Authors: Robert L Cook; Zhi Zhou; Maria Jose Miguez; Clery Quiros; Luis Espinoza; John E Lewis; Babette Brumback; Kendall Bryant Journal: Alcohol Clin Exp Res Date: 2019-07-10 Impact factor: 3.455